Ribom D - Search Results

1

A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival.

Elsir T, Edqvist PH, Carlson J, Ribom D, Bergqvist M, Ekman S, Popova SN, Alafuzoff I, Ponten F, Nistér M, Smits A. Elsir T, et al. Among authors: ribom d. Int J Cancer. 2014 Mar 1;134(5):1123-31. doi: 10.1002/ijc.28441. Epub 2013 Sep 16. Int J Cancer. 2014. PMID: 24037901

2

PROX1 is a predictor of survival for gliomas WHO grade II.

Elsir T, Qu M, Berntsson SG, Orrego A, Olofsson T, Lindström MS, Nistér M, von Deimling A, Hartmann C, Ribom D, Smits A. Elsir T, et al. Among authors: ribom d. Br J Cancer. 2011 May 24;104(11):1747-54. doi: 10.1038/bjc.2011.162. Epub 2011 May 10. Br J Cancer. 2011. PMID: 21559010 Free PMC article.

3

Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas.

Ribom D, Smits A. Ribom D, et al. Neurol Res. 2005 Jul;27(5):516-21. doi: 10.1179/174313213X13789811969265. Neurol Res. 2005. PMID: 15978178

4

Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, Bolander H, Bergström M, Smits A. Ribom D, et al. Cancer. 2001 Sep 15;92(6):1541-9. doi: 10.1002/1097-0142(20010915)92:6<1541::aid-cncr1480>3.0.co;2-d. Cancer. 2001. PMID: 11745233

5

Prognostic value of platelet derived growth factor alpha receptor expression in grade 2 astrocytomas and oligoastrocytomas.

Ribom D, Andrae J, Frielingsdorf M, Hartman M, Nistér M, Smits A. Ribom D, et al. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):782-7. doi: 10.1136/jnnp.72.6.782. J Neurol Neurosurg Psychiatry. 2002. PMID: 12023424 Free PMC article.

6

On the issue of early and aggressive treatment in grade 2 gliomas.

Ribom D, Smits A, Hartman M, Persson L, Blomquist E. Ribom D, et al. J Cancer Res Clin Oncol. 2003 Mar;129(3):154-60. doi: 10.1007/s00432-003-0423-0. Epub 2003 Mar 12. J Cancer Res Clin Oncol. 2003. PMID: 12712330

7

Epileptic seizures and survival in early disease of grade 2 gliomas.

Danfors T, Ribom D, Berntsson SG, Smits A. Danfors T, et al. Among authors: ribom d. Eur J Neurol. 2009 Jul;16(7):823-31. doi: 10.1111/j.1468-1331.2009.02599.x. Epub 2009 Mar 26. Eur J Neurol. 2009. PMID: 19473357

8

Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Smits A, Westerberg E, Ribom D. Smits A, et al. Among authors: ribom d. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):65-71. doi: 10.1007/s00259-007-0531-1. Epub 2007 Aug 21. Eur J Nucl Med Mol Imaging. 2008. PMID: 17710394

9

Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas.

Ribom D, Engler H, Blomquist E, Smits A. Ribom D, et al. Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40. doi: 10.1007/s00259-002-0762-0. Epub 2002 Mar 5. Eur J Nucl Med Mol Imaging. 2002. PMID: 11976801

10

Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas.

Ribom D, Westman-Brinkmalm A, Smits A, Davidsson P. Ribom D, et al. Tumour Biol. 2003 Mar-Apr;24(2):94-9. doi: 10.1159/000071082. Tumour Biol. 2003. PMID: 12853704

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters